| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Chia-Chi Lin; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-09-15T01:08:46Z |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-07-13T06:04:28Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; LEE JIH-HSIANG; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-04-23T05:56:30Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
De Bono J.;Lin C.-C.;Chen L.-T.;Corral J.;Michalarea V.;Rihawi K.;Ong M.;Lee J.-H.;Hsu C.-H.;Chih-Hsin Yang;Shiah H.-S.;Yen C.-J.;Anthoney A.;Jove M.;Buschke S.;Fuertig R.;Schmid U.;Goeldner R.-G.;Strelkowa N.;Huang D.C.-L.;Bogenrieder T.;Twelves C.;Cheng A.-L.; de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; CHIH-HSIN YANG; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-10T02:36:29Z |
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
|
Schmid P.; Sablin M.-P.; Bergh J.; Im S.-A.; YEN-SHEN LU; Mart?nez N.; Neven P.; Lee K.S.; Morales S.; P?rez-Fidalgo J.A.; Adamson D.; Gon?alves A.; Prat A.; Jerusalem G.; Schlieker L.; Espadero R.-M.; Bogenrieder T.; Huang D.C.-L.; Crown J.; Cort?s J. |
| 國立成功大學 |
2021 |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park, K.;Tan, D.S.W.;Su, W.-C.;Cho, B.C.;Kim, S.-W.;Lee, K.H.;Wang, C.-C.;Seto, T.;Huang, D.C.-L.;Jung, H.H.;Hsu, M.-C.;Bogenrieder, T.;Lin, C.-C. |
| 臺大學術典藏 |
2020-05-25T07:35:00Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
Bogenrieder T; Twelves C; Cheng A.-L.; Huang D.C.-L; Strelkowa N; Goeldner R.-G; Schmid U; Fuertig R; Buschke S; Jove M; Anthoney A; Yen C.-J; de Bono J; Chia-Chi Lin; Chen L.-T; Corral J; Michalarea V; Rihawi K; Ong M; Lee J.-H; Hsu C.-H; Yang J.C.-H; Shiah H.-S |
| 臺大學術典藏 |
2020-04-28T07:25:09Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
Cheng A.-L.; Twelves C.; Bogenrieder T.; Huang D.C.-L.; Strelkowa N.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Shiah H.-S.; Yang J.C.-H.; CHIH-HUNG HSU; Lee J.-H.; de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; De Bono J.;Lin C.-C.;Chen L.-T.;Corral J.;Michalarea V.;Rihawi K.;Ong M.;Lee J.-H.;Chih-Hung Hsu;Yang J.C.-H.;Shiah H.-S.;Yen C.-J.;Anthoney A.;Jove M.;Buschke S.;Fuertig R.;Schmid U.;Goeldner R.-G.;Strelkowa N.;Huang D.C.-L.;Bogenrieder T.;Twelves C.;Cheng A.-L. |
